Munger Mode rating: 2 out of 5 — Sell. Our own rating from the research report below, on business quality first: moat durability and management, with price separating the top three.
We rely on UnitedHealth's Q3 2026 10-Q (period ended September 30, 2026), the Q3 earnings release and call of October 13, and what we know of the sector's history. Price caveat. Our searches did not return a verified closing price for today, and we won't invent one. The anchors we can document are these: UNH fell about 20% on January 27 after CMS's preliminary 2027 Medicare Advantage rate came in at roughly 0.09%. It traded near $281 in early April after the final 2.48% rate. The company's forward-repurchase counterparty bought 6.4 million shares in 2026 at an average of $312.73. The stock rose more than 4% premarket on October 13 after Q3 results. We therefore use $330 as a working reference price and show every valuation conclusion as a function of price. Please check this against a live quote before acting. Our rating changes only below about $270.
Recent filings analysed: 8-K (2026-11-09), 10-Q (2026-11-03), 8-K (2026-10-13), 8-K (2026-09-08).
Stock screener · Superinvestor 13F holdings · Analyst sentiment